| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 12 | 2024 | 395 | 4.100 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2022 | 195 | 2.350 |
Why?
|
| Neoplasms | 16 | 2024 | 3035 | 2.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 6 | 2024 | 170 | 2.050 |
Why?
|
| Immunotherapy | 13 | 2023 | 669 | 1.820 |
Why?
|
| Tumor Microenvironment | 10 | 2024 | 459 | 1.720 |
Why?
|
| Kidney Neoplasms | 5 | 2024 | 635 | 1.240 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1215 | 1.140 |
Why?
|
| B7-H1 Antigen | 5 | 2024 | 273 | 1.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2016 | 155 | 1.000 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2024 | 435 | 0.960 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 3 | 2024 | 24 | 0.940 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2023 | 170 | 0.850 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2024 | 967 | 0.760 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 394 | 0.760 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2021 | 88 | 0.730 |
Why?
|
| Urothelium | 1 | 2020 | 71 | 0.720 |
Why?
|
| HLA Antigens | 1 | 2021 | 227 | 0.690 |
Why?
|
| Immunity | 2 | 2019 | 141 | 0.690 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 1543 | 0.680 |
Why?
|
| Venae Cavae | 1 | 2019 | 13 | 0.670 |
Why?
|
| Antigens, Neoplasm | 2 | 2020 | 332 | 0.630 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 285 | 0.630 |
Why?
|
| Ascites | 1 | 2018 | 56 | 0.610 |
Why?
|
| Biopsy | 3 | 2016 | 1182 | 0.610 |
Why?
|
| Sulfonamides | 2 | 2016 | 317 | 0.580 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 1223 | 0.560 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 139 | 0.560 |
Why?
|
| Humans | 43 | 2024 | 89063 | 0.550 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 250 | 0.530 |
Why?
|
| Carcinoma | 1 | 2019 | 443 | 0.530 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 315 | 0.460 |
Why?
|
| Precision Medicine | 1 | 2018 | 410 | 0.450 |
Why?
|
| Pyrimidines | 1 | 2016 | 372 | 0.450 |
Why?
|
| Silicic Acid | 1 | 2013 | 1 | 0.450 |
Why?
|
| Aluminum Hydroxide | 1 | 2013 | 3 | 0.450 |
Why?
|
| Antacids | 1 | 2013 | 4 | 0.450 |
Why?
|
| Magnesium Oxide | 1 | 2013 | 4 | 0.450 |
Why?
|
| Sodium Bicarbonate | 1 | 2013 | 9 | 0.440 |
Why?
|
| Alginates | 1 | 2013 | 16 | 0.440 |
Why?
|
| Postprandial Period | 1 | 2013 | 47 | 0.430 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 131 | 0.430 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 599 | 0.420 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2011 | 3 | 0.390 |
Why?
|
| Actinomyces | 1 | 2011 | 5 | 0.390 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2011 | 9 | 0.390 |
Why?
|
| Actinomycosis | 1 | 2011 | 12 | 0.390 |
Why?
|
| Gastroesophageal Reflux | 1 | 2013 | 122 | 0.380 |
Why?
|
| Lymphoma | 2 | 2023 | 265 | 0.370 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1114 | 0.350 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 260 | 0.340 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2023 | 319 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 2552 | 0.320 |
Why?
|
| beta Catenin | 3 | 2021 | 266 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 3443 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 3000 | 0.300 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 306 | 0.290 |
Why?
|
| Lymph Nodes | 1 | 2011 | 548 | 0.290 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 594 | 0.290 |
Why?
|
| Melanoma | 2 | 2023 | 467 | 0.290 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 2347 | 0.280 |
Why?
|
| Indazoles | 2 | 2016 | 67 | 0.270 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 751 | 0.270 |
Why?
|
| Treatment Outcome | 7 | 2024 | 8203 | 0.250 |
Why?
|
| Organosilicon Compounds | 1 | 2004 | 4 | 0.240 |
Why?
|
| Silver | 1 | 2004 | 16 | 0.240 |
Why?
|
| Alkynes | 1 | 2004 | 18 | 0.240 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 48 | 0.230 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2024 | 44 | 0.230 |
Why?
|
| Nitriles | 1 | 2024 | 160 | 0.230 |
Why?
|
| Signal Transduction | 4 | 2024 | 3373 | 0.220 |
Why?
|
| Middle Aged | 10 | 2024 | 25863 | 0.220 |
Why?
|
| Benzamides | 1 | 2024 | 237 | 0.220 |
Why?
|
| Wnt Signaling Pathway | 2 | 2021 | 97 | 0.220 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2024 | 131 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1149 | 0.210 |
Why?
|
| Disease Progression | 2 | 2018 | 1488 | 0.210 |
Why?
|
| Capecitabine | 2 | 2024 | 98 | 0.210 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1429 | 0.210 |
Why?
|
| Maytansine | 1 | 2022 | 10 | 0.210 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 121 | 0.210 |
Why?
|
| Urologic Neoplasms | 2 | 2023 | 82 | 0.200 |
Why?
|
| Female | 13 | 2024 | 46011 | 0.200 |
Why?
|
| Urinary Bladder | 1 | 2024 | 246 | 0.200 |
Why?
|
| Cisplatin | 2 | 2024 | 617 | 0.190 |
Why?
|
| Immunoconjugates | 1 | 2022 | 110 | 0.190 |
Why?
|
| Aged | 10 | 2024 | 19077 | 0.190 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 41 | 0.190 |
Why?
|
| Quinolines | 1 | 2021 | 91 | 0.190 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 114 | 0.190 |
Why?
|
| Repressor Proteins | 1 | 2024 | 423 | 0.180 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 1108 | 0.180 |
Why?
|
| Dendritic Cells | 1 | 2024 | 442 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1400 | 0.180 |
Why?
|
| Immunomodulation | 2 | 2018 | 58 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2023 | 429 | 0.170 |
Why?
|
| Mutation | 4 | 2024 | 4132 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 275 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 373 | 0.160 |
Why?
|
| Microbiota | 1 | 2023 | 398 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1265 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 280 | 0.150 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 344 | 0.150 |
Why?
|
| Animals | 8 | 2024 | 27317 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1650 | 0.150 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 60 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 93 | 0.140 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2016 | 1 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 244 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2017 | 61 | 0.140 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 17 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 504 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 604 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 506 | 0.140 |
Why?
|
| Tumor Escape | 1 | 2016 | 51 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 6777 | 0.140 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 141 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 309 | 0.130 |
Why?
|
| PPAR gamma | 1 | 2016 | 73 | 0.130 |
Why?
|
| Patient Selection | 1 | 2019 | 682 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 1 | 2016 | 168 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 267 | 0.130 |
Why?
|
| Prognosis | 2 | 2020 | 3773 | 0.130 |
Why?
|
| Male | 10 | 2024 | 42251 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2016 | 371 | 0.130 |
Why?
|
| Recurrence | 1 | 2018 | 1140 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2016 | 682 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 393 | 0.120 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 22 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1710 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2021 | 2863 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2021 | 758 | 0.120 |
Why?
|
| Awareness | 1 | 2014 | 89 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 736 | 0.120 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 108 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 308 | 0.110 |
Why?
|
| Esophageal pH Monitoring | 1 | 2013 | 12 | 0.110 |
Why?
|
| Manometry | 1 | 2013 | 44 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 540 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2013 | 202 | 0.110 |
Why?
|
| Electric Impedance | 1 | 2013 | 110 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 876 | 0.110 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 389 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 499 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2657 | 0.100 |
Why?
|
| Cystectomy | 2 | 2024 | 105 | 0.100 |
Why?
|
| Contrast Media | 1 | 2016 | 1090 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 2552 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 2411 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 433 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 364 | 0.090 |
Why?
|
| Adult | 5 | 2023 | 26507 | 0.090 |
Why?
|
| Mice | 5 | 2024 | 11737 | 0.090 |
Why?
|
| Databases, Genetic | 2 | 2021 | 263 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1714 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2014 | 780 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1591 | 0.070 |
Why?
|
| Inflammation | 1 | 2012 | 971 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 3209 | 0.060 |
Why?
|
| Cyclization | 1 | 2004 | 11 | 0.060 |
Why?
|
| 4-1BB Ligand | 1 | 2024 | 3 | 0.060 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2024 | 22 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2024 | 17 | 0.060 |
Why?
|
| Phenotype | 2 | 2021 | 2439 | 0.060 |
Why?
|
| Catalysis | 1 | 2004 | 205 | 0.060 |
Why?
|
| Perforin | 1 | 2023 | 55 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2004 | 289 | 0.060 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 122 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2362 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2021 | 2880 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 576 | 0.050 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2021 | 2 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 19 | 0.050 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2021 | 23 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 272 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2023 | 491 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 80 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 66 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 321 | 0.050 |
Why?
|
| Interferons | 1 | 2021 | 124 | 0.050 |
Why?
|
| Wnt Proteins | 1 | 2021 | 130 | 0.040 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2021 | 124 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 27 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 171 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 39 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 192 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2019 | 52 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 88 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 112 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2018 | 169 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 220 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1363 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1574 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 802 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 740 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1855 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 1796 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 216 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 570 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2019 | 382 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 2001 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 23 | 0.030 |
Why?
|
| Personnel, Hospital | 1 | 2014 | 30 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1889 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 1670 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2012 | 68 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 5320 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 385 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 1755 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 2335 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3657 | 0.020 |
Why?
|
| Inpatients | 1 | 2014 | 310 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2014 | 395 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 695 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 859 | 0.020 |
Why?
|
| Glioma | 1 | 2012 | 293 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 988 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 459 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1706 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 699 | 0.020 |
Why?
|
| United States | 1 | 2021 | 6955 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 573 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2014 | 1041 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 9003 | 0.020 |
Why?
|